[Are antiangiogenic antibodies universal for solid tumor?].

Area of Science:

• Oncology
• Molecular Biology
• Biomedical Engineering

Context:

• Tumor growth beyond 1-2 mm³ necessitates sustained angiogenesis.
• Normal adult vasculature exhibits quiescent endothelial cells.
• Vascular endothelial growth factor (VEGF) and its receptors are critical regulators of angiogenesis.

Purpose:

• To review recent developments in angiogenesis inhibitors for cancer treatment.
• To highlight the transition of angiogenesis inhibitors from research to clinical application.
• To focus on the therapeutic potential of VEGF-targeted agents.

Summary:

• Angiogenesis inhibitors, particularly those targeting VEGF, have transitioned from theoretical concepts to practical anticancer therapies.
• Solid tumor expansion is critically dependent on continuous vascular growth and remodeling.
• Numerous VEGF-targeted inhibitory agents are under investigation for various cancer types.

Impact:

• Provides an overview of current research on angiogenesis inhibitors in oncology.
• Focuses on the application of these inhibitors in treating breast, lung, and colorectal cancers.
• Offers insights into the evolving landscape of cancer treatment strategies.